miR-506 suppresses cervical cancer cell proliferation both in vitro and in vivo

Rok, strany: 2018, 331 - 338

Cervical cancer (CC) is one of the most common gynecological malignancies in women worldwide. Recently increasing evidences indicate aberrant expression of miR-506 was reported to be associated with a variety of tumors. The aimof this study was to evaluate the potential role of miR-506 in CC and verify its effect on the regulation of ABCC4. The expression of miR-506 in cervical cancer tissues and HeLa and C33A cell lines was examined using quantitative Real-time PCR. MTT assay and animals studies were use to examine the effects of miR-506 on cervical cancer proliferation. Luciferase reporter and western blot were used to confirm miR-506 could regulate ABCC4. We found that miR-506 was significantly downregulated in human CC cell lines (HeLa and C33A) and clinical CC specimens as compared with matched cell lines and adjacent normal tissues, while the expression level of ABCC4 was higher in tumor tissues than it in adjacent normal tissues. We also revealed that up-regulated expression of miR-506 could inhibit CC cells proliferation both in vitro and in vivo. Moreover, ABCC4 was identified as a direct target of miR-506 and the inverse relationship between them was also observed. In summary, our finding suggests that miR-506 acts an important role in suppressing CC cell proliferation and suppresses the expression of ABCC4 by directly targeting its 3’-UTR. miR-506 may represent a novel therapeutic target of microRNA-mediated suppression of cell proliferation in CC, but the role of the miR-506/ABCC4 axis in CC progression needs further study.

ISO 690:

Gong, M., Chen, C., Zhao, H., Sun, M., Song, M. 2018. miR-506 suppresses cervical cancer cell proliferation both in vitro and in vivo. In NEOPLASMA, vol. 65, no.3, pp. 331-338. 0028-2685.

APA:

Gong, M., Chen, C., Zhao, H., Sun, M., Song, M. (2018). miR-506 suppresses cervical cancer cell proliferation both in vitro and in vivo. NEOPLASMA, 65(3), 331-338. 0028-2685.